Record mula sa primary source
Decision-gradeTopline na resulta
Theravance: Inaasahan ang topline readout ng Phase 3 CYPRESS trial ng ampreloxetine sa Q1 2026
Natapos na ang open-label portion ng pivotal Phase 3 CYPRESS study ng ampreloxetine. Nasa track ang topline results para sa Q1 2026. Plano ng kumpanya ang expedited NDA submission at priority review request kung supportive ang data.
Mahahalagang fact
- Na-file
- Nob 10, 2025, 09:11 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Neutral
- Kumpanya
TBPHTheravance Biopharma- Asset
- ampreloxetine
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- Kalendaryo
- Resulta ng trial · Ene 1, 2026 · Positibo
Sipi mula sa source
EX-99.1 2 tm2530676d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update · YUPELRI ® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability · Open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026 · Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025 · TRELEGY year-to-date sales on track to achieve $50 million milestone in 2025 2 · Strong balance sheet with $333 million in cash and no debt DUBLIN, IRELAND – NOVEMBER 10, 2025 – Theravance Biopharma, Inc. (“Theravance Biopharma” or
Higit pa tungkol sa asset na ito
Kapansin-pansin
Dis 8, 2025
11:29 AM
TBPHTheravance BiopharmaMagsasagawa ang Theravance Biopharma ng Ampreloxetine KOL Event sa Disyembre 8, 2025